Recent advanced transcriptome analyses have uncovered thousands of splice variants and long non-coding (lnc)RNAs, providing new sources for biomarker discovery. Given the complexity of the transcriptome, however, finding informative expression biomarkers is challenging, time-consuming, and costly. Clariom assays, built using the latest transcriptome knowledge from multiple databases, are simple and fast tools for finding high-fidelity expression biomarkers. They are compatible with clinical research samples, available in scalable formats for different throughput needs, and include flexible, intuitive software for fast and simple analysis.
In addition, our new Clariom GO Screen provides high throughput, low-cost secondary screening of drug compounds in gene expression research. Learn more ›
The Clariom portfolio offers diverse assays for diverse customers’ needs. The Clariom D Assay is designed with deep content and facilitates complete transcriptome analysis, including coverage of novel non-coding transcripts and splice isoforms. The Clariom S Assay is best suited to obtain a gene-level view of the transcriptome and provides a fast, simple, and scalable path to generating the results you need for your research. The Clariom GO Screen is designed for high-throughput secondary screening of drug compounds and is offered as a service through verified service providers.
Comprising arrays, reagents, and intuitive analysis software, Applied Biosystems Clariom assays deliver comprehensive transcriptome-wide results quickly and easily—even with challenging samples.
With increased knowledge of the transcriptome, a growing body of evidence has implicated lncRNAs as critical regulators of coding RNA and alternative splicing. Aberrant expression of these regulatory lncRNAs has been increasingly documented in a wide range of diseases, establishing their potential for future use as biomarkers and therapeutic agents.
Figure 1. 13 candidate dysregulated lncRNAs identified by transcriptome-level assays were verified by qRT-PCR. Of those, eight samples expressed statistically significant differences in infected (T) vs. control (C) cells. qRT-PCR verification of the same eight samples revealed four lncRNAs that were significantly differentially expressed in H. pylori-positive (P) vs. H. pylori-negative (N) cells. Zhu, H., et al. Microarray analysis of long non-coding RNA expression profiles in human gastric cells and tissues with Helicobacter pylori infection. BMC Medical Genomics 8:84 (2015).*
Figure 2. HTA & Clariom D human arrays deliver the equivalent accuracy in gene expression measurements throughout the transcriptome as sequencing a sample across 2 full lanes on a HiSeq™ 2000 System. By evaluating a linear tissue mixture model in which RNA from 2 samples are mixed in known proportions, the accuracy of expression was evaluated across all measured exons. The y-axis is the calculated error or, mean absolute deviation (MAD), (median(|x - median(x)|) of (D-C)/(B-A)) where A = Universal Human Reference RNA (UHRR), Agilent Technologies, Inc.; B = Human Brain Reference RNA (HBRR), Life Technologies, Inc.; C = 75%A/25%B; and D = 25%A/75%B.. Array MAD was calculated from all combinations of n = 3 arrays per sample, where n = 4 arrays per sample were available. Box plots display all 256 possible combinations of n = 3 arrays per sample, with box plot whiskers representing the min and max MAD value. Array target was prepared using the GeneChip WT PLUS reagent kit from 100ng of total RNA.
Whether you need a deep and broad high-resolution transcriptome profile, or are focused on gene-level changes on the surface of the transcriptome, Clariom assays generate reproducible data and offer the level of coverage you need to find biomarkers. Fast analysis yields results. Now.
Clariom D Assay
Clariom S Assay
Clariom GO Screen
|FFPE tissue compatible?||Yes||Yes||No|
|Sample input from direct lysis of cells?||No||No||Yes|
|Typical study size (no. of samples)||12–1000||12–1000||1,000–500,000|
|RNA input minimum||50 ng; 0.01 ng (0.5 ng for FFPE) with Pico assay||50 ng; 0.01 ng (0.5 ng for FFPE) with Pico assay||0.1 ng target (5 μL lysate at 100 cells/μL)|
|Application(s)||Deep and broad transcriptome analysis and biomarker discovery||Gene level expression profiling of well-annotated genes||Secondary screening of drug compounds and hit profiling|
|Level of analysis||Coding and non-coding genes, exons, and alt splicing, including both well-annotated and speculative transcripts||Well-annotated genes||Well-annotated genes with probes designed from Gene Ontology Consortium|
|Format(s)||Cartridge (single sample)||Cartridge (single sample); array plates (24/96 samples)||Array plates (384 samples)|
|Available species||Human, mouse, rat||Human, mouse, rat||Human*|
|Instrument (array format)||GeneChip Scanner 3000 7G System (cartridge)||GeneChip Scanner 3000 7G System (cartridge)|
*inquire about other species
Figure 3. TAC Software WikiPathways integration view. Identify a greater number of relevant and differentially expressed genes with pathway visualizations.
Clariom assays are available for human, mouse and rat, with Pico reagents for challenging samples, and in various throughput formats to meet your applications needs. Custom designs are available for other species.
For Research Use Only. Not for use in diagnostic procedures.